Beacon Therapeutics

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023, aiming to restore and improve vision for patients suffering from a range of prevalent and rare retinal diseases that cause blindness. The company has a solid scientific foundation, combining a late-stage development candidate for the treatment of X-linked retinitis pigmentosa (XLRP) with two preclinical programs—one targeting dry age-related macular degeneration (AMD) and the other licensed from Oxford University, targeting cone-rod dystrophy (CRD).